SMT201500091B - Composti di bis(fluoroachil)-1,4-benzodiazepinone - Google Patents

Composti di bis(fluoroachil)-1,4-benzodiazepinone

Info

Publication number: SMT201500091B
Authority: SM; San Marino
Prior art keywords: fluoroachyl; bis; benzodiazepinone compounds; benzodiazepinone; compounds
Prior art date: 2011-03-22

Application number

SM201500091T

Other languages

English (en)

Inventor

Ashvinikumar Gavai

Soong-Hoon Kim

Claude Quesnelle

Francis Lee

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-22

Filing date

2015-04-13

Publication date

2015-05-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2015-05-05 Publication of SMT201500091B publication Critical patent/SMT201500091B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

SM201500091T 2011-03-22 2015-04-13 Composti di bis(fluoroachil)-1,4-benzodiazepinone SMT201500091B (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161466238P	2011-03-22	2011-03-22
PCT/US2012/030021 WO2012129353A1 (en)	2011-03-22	2012-03-22	Bis(fluoroalkyl)-1,4-benzodiazepinone compounds

Publications (1)

Publication Number	Publication Date
SMT201500091B true SMT201500091B (it)	2015-05-05

Family

ID=45894701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201500091T SMT201500091B (it)	2011-03-22	2015-04-13	Composti di bis(fluoroachil)-1,4-benzodiazepinone

Country Status (32)

Country	Link
US (2)	US8629136B2 (it)
EP (1)	EP2688873B1 (it)
JP (1)	JP5873923B2 (it)
KR (1)	KR101948347B1 (it)
CN (1)	CN103717576B (it)
AR (2)	AR085471A1 (it)
AU (1)	AU2012230904B2 (it)
BR (1)	BR112013024059B1 (it)
CA (1)	CA2830902C (it)
CL (1)	CL2013002690A1 (it)
CO (1)	CO6771446A2 (it)
CY (1)	CY1116423T1 (it)
DK (1)	DK2688873T3 (it)
EA (1)	EA022530B1 (it)
ES (1)	ES2534080T3 (it)
HR (1)	HRP20150273T1 (it)
IL (1)	IL228534A (it)
MA (1)	MA35036B1 (it)
MX (1)	MX2013010420A (it)
MY (1)	MY161233A (it)
PE (1)	PE20140626A1 (it)
PH (1)	PH12013501738B1 (it)
PL (1)	PL2688873T3 (it)
PT (1)	PT2688873E (it)
RS (1)	RS53843B1 (it)
SG (1)	SG193555A1 (it)
SI (1)	SI2688873T1 (it)
SM (1)	SMT201500091B (it)
TN (1)	TN2013000372A1 (it)
TW (1)	TWI530489B (it)
UY (1)	UY33961A (it)
WO (1)	WO2012129353A1 (it)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8883145B2 (en)	2009-10-16	2014-11-11	Oncomed Pharmaceuticals, Inc.	Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
LT3485903T (lt)	2011-09-23	2023-02-27	Mereo Biopharma 5, Inc.	Vegf/ dll4 surišantys agentai ir jų panaudojimas
JP2015534554A (ja)	2012-09-21	2015-12-03	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
TWI614238B (zh) *	2012-09-21	2018-02-11	必治妥美雅史谷比公司	雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
EP2897942B1 (en) *	2012-09-21	2016-08-31	Bristol-Myers Squibb Company	Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
EP2897946B1 (en) *	2012-09-21	2016-11-16	Bristol-Myers Squibb Company	N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors
EP2897960B1 (en)	2012-09-21	2016-08-03	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds as notch inhibitors
WO2014047370A1 (en) *	2012-09-21	2014-03-27	Bristol-Myers Squibb Company	Fluoroalkyl dibenzodiazepinone compounds
EP2897941B1 (en) *	2012-09-21	2016-09-07	Bristol-Myers Squibb Company	Prodrugs of 1,4-benzodiazepinone compounds
EP2897944B1 (en)	2012-09-21	2016-10-26	Bristol-Myers Squibb Company	Substituted 1,5-benzodiazepinone compounds
JP2015529252A (ja)	2012-09-21	2015-10-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	フルオロアルキル−１，４−ベンゾジアゼピノン化合物
US9599620B2 (en)	2012-10-31	2017-03-21	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a DLL4 antagonist
CN105101968A (zh)	2013-04-04	2015-11-25	百时美施贵宝公司	治疗增殖性疾病的组合疗法
WO2015013579A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Compositions to improve the therapeutic benefit of bisantrene
CN103435562B (zh) *	2013-08-26	2016-02-24	华东理工大学	6-取代苯并二氮卓-2,4-二酮类化合物及其用途
EP3212233B1 (en) *	2014-10-31	2020-06-24	Oncomed Pharmaceuticals, Inc.	Combination therapy for treatment of disease
WO2016066115A1 (zh) *	2014-10-31	2016-05-06	厦门大学	取代杂环衍生物、其制备方法和用途
CN104356082B (zh) *	2014-10-31	2016-07-13	厦门大学	一类取代杂环衍生物及其制备方法
CN104352488B (zh) *	2014-10-31	2016-08-31	厦门大学	一类取代杂环衍生物在制备治疗疼痛药物中的应用
CN104892532B (zh) *	2015-05-20	2017-09-08	成都理工大学	手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺
RS63653B1 (sr)	2015-07-22	2022-11-30	Enanta Pharm Inc	Benzodiazepinski derivati kao inhibitori rsv
AU2016326609B2 (en)	2015-09-23	2023-03-09	Mereo Biopharma 5, Inc.	Methods and compositions for treatment of cancer
WO2017123884A1 (en)	2016-01-15	2017-07-20	Enanta Pharmaceuticals, Inc.	Heterocyclic compounds as rsv inhibitors
EP3429571B1 (en)	2016-03-15	2025-10-08	Oryzon Genomics, S.A.	Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2018152413A1 (en)	2017-02-16	2018-08-23	Enanta Pharmaceuticals, Inc.	Processes for the preparation of benzodiazepine derivatives
WO2018201056A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018226801A1 (en)	2017-06-07	2018-12-13	Enanta Pharmaceuticals, Inc.	Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en)	2017-06-30	2019-01-03	Enanta Pharmaceuticals, Inc.	HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en)	2017-06-30	2021-08-17	Enanta Pharmaceuticals, Inc.	Heterocyclic compounds as RSV inhibitors
ES2817910T3 (es) *	2017-08-04	2021-04-08	Alzheimur 2012 S L	Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
WO2019067864A1 (en)	2017-09-29	2019-04-04	Enanta Pharmaceuticals, Inc.	PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
JP7447006B2 (ja)	2017-11-01	2024-03-11	ジュノーセラピューティクスインコーポレイテッド	Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12193994B2 (en)	2017-11-06	2025-01-14	Juno Therapeutics, Inc.	Combination of a cell therapy and a gamma secretase inhibitor
US10647711B2 (en)	2017-11-13	2020-05-12	Enanta Pharmaceuticals, Inc.	Azepin-2-one derivatives as RSV inhibitors
CN111343990B (zh) *	2017-11-13	2023-08-04	英安塔制药有限公司	苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法
US10975094B2 (en)	2018-04-11	2021-04-13	Enanta Pharmaceuticals, Inc.	Heterocyclic compounds as RSV inhibitors
WO2019217250A1 (en) *	2018-05-06	2019-11-14	Ayala Pharmaceuticals Inc.	Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
WO2019215585A1 (en) *	2018-05-06	2019-11-14	Ayala Pharmaceuticals Inc.	Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
SG11202011327UA (en) *	2018-05-15	2020-12-30	Ayala Pharmaceuticals Inc	Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
BR112020023204A2 (pt) *	2018-05-15	2021-02-23	Bristol-Myers Squibb Company	composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos
BR112020023975A2 (pt) *	2018-05-24	2021-02-23	Ayala Pharmaceuticals Inc.	composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
IL317554A (en)	2018-06-01	2025-02-01	Novartis Ag	Anti-BCMA binding molecules and their uses
UY38614A (es)	2019-03-18	2020-10-30	Enanta Pharm Inc	Derivados de benzodiazepinas como inhibidores del rsv
WO2020210246A1 (en)	2019-04-09	2020-10-15	Enanta Pharmaceuticals, Inc,	Heterocyclic compounds as rsv inhibitors
JP2022533100A (ja) *	2019-05-15	2022-07-21	アヤラファーマシューティカルズインコーポレイテッド	Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
TW202115114A (zh)	2019-06-24	2021-04-16	瑞士商諾華公司	針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
US11505558B1 (en)	2019-10-04	2022-11-22	Enanta Pharmaceuticals, Inc.	Antiviral heterocyclic compounds
MX2022003984A (es)	2019-10-04	2022-07-27	Enanta Pharm Inc	Compuestos heterociclicos antivirales.
UY39032A (es)	2020-01-24	2021-07-30	Enanta Pharm Inc	Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en)	2020-07-07	2022-12-27	Enanta Pharmaceuticals, Inc.	Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
IL301060A (en)	2020-09-03	2023-05-01	Bristol Myers Squibb Co	Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepine compounds and their uses
WO2022086840A1 (en)	2020-10-19	2022-04-28	Enanta Pharmaceuticals, Inc.	Heterocyclic compounds as anti-viral agents
WO2022122667A1 (en)	2020-12-07	2022-06-16	Cellestia Biotech Ag	Pharmaceutical combinations for treating cancer
EP4008324A1 (en)	2020-12-07	2022-06-08	Cellestia Biotech AG	Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
KR20230161976A (ko)	2021-02-26	2023-11-28	이난타 파마슈티칼스, 인코포레이티드	항바이러스성 헤테로사이클릭 화합물
EP4346816A2 (en)	2021-06-02	2024-04-10	Cellestia Biotech AG	Compounds for use in a method for treating an autoimmune and inflammatory disease
US20250000870A1 (en)	2021-11-08	2025-01-02	Cellestia Biotech Ag	Pharmaceutical Combinations for Treating Cancer
EP4223292A1 (en)	2022-02-07	2023-08-09	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
AR129003A1 (es)	2022-04-07	2024-07-03	Enanta Pharm Inc	Compuestos heterocíclicos antivirales
WO2023211997A1 (en)	2022-04-27	2023-11-02	Enanta Pharmaceuticals, Inc.	Antiviral compounds
WO2024145306A1 (en) *	2022-12-28	2024-07-04	Ayala Pharmaceuticals Inc.	Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5324726A (en)	1989-12-18	1994-06-28	Merck & Co., Inc.	Benzodiazepine analogs
AU2555997A (en) *	1996-04-03	1997-10-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5852010A (en)	1996-04-03	1998-12-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6635632B1 (en)	1996-12-23	2003-10-21	Athena Neurosciences, Inc.	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
US6737038B1 (en)	1998-11-12	2004-05-18	Bristol-Myers Squibb Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
DE69926254D1 (de)	1998-11-12	2005-08-25	Bristol Myers Squibb Pharma Co	Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
CA2347671A1 (en)	1998-12-24	2000-07-06	Dupont Pharmaceuticals Company	Succinoylamino benzodiazepines as inhibitors of a.beta. protein production
MXPA01011052A (es)	1999-04-30	2002-11-22	Univ Michigan	Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
US6503902B2 (en)	1999-09-13	2003-01-07	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en)	1999-09-13	2005-11-01	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997700A (en)	1999-10-08	2001-04-23	Du Pont Pharmaceuticals Company	Amino lactam sulfonamides as inhibitors of abeta protein production
CZ20022332A3 (cs) *	2000-01-07	2003-01-15	Transform Pharmaceuticals, Inc.	Sestava vzorků
JP2003520266A (ja)	2000-01-24	2003-07-02	メルクシャープエンドドームリミテッド	γ−セクレターゼ阻害薬
JP2003523345A (ja)	2000-02-17	2003-08-05	ブリストル−マイヤーズスクイブファーマカンパニー	Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
US6495540B2 (en)	2000-03-28	2002-12-17	Bristol - Myers Squibb Pharma Company	Lactams as inhibitors of A-β protein production
WO2001074796A1 (en)	2000-03-31	2001-10-11	Bristol-Myers Squibb Pharma Company	SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2404023A1 (en)	2000-04-03	2001-10-11	Richard E. Olson	Cyclic lactams as inhibitors of a.beta. protein production
US6713476B2 (en)	2000-04-03	2004-03-30	Dupont Pharmaceuticals Company	Substituted cycloalkyls as inhibitors of a beta protein production
GB0008710D0 (en)	2000-04-07	2000-05-31	Merck Sharp & Dohme	Therapeutic compounds
JP2004500419A (ja)	2000-04-11	2004-01-08	デュポン　ファーマシューティカルズ　カンパニー	Ａβタンパク質産生阻害剤としての置換ラクタム
AU2001261728A1 (en)	2000-05-17	2001-11-26	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en) *	2000-05-24	2000-07-19	Merck Sharp & Dohme	Therapeutic agents
HK1049333A1 (zh)	2000-06-01	2003-05-09	Bristol-Myers Squibb Pharma Company	以环状琥珀酸酯代替内酰胺，作为制造Aβ蛋白质的抑制剂
US7001901B2 (en)	2002-08-27	2006-02-21	Bristol-Myers Squibb Company	Tetrazolylpropionamides as inhibitors of Aβ protein production
NZ538870A (en)	2002-09-20	2007-04-27	Arrow Therapeutics Ltd	Benzodiazepine derivatives and pharmaceutical compositions containing them
MXPA05008172A (es)	2003-02-04	2005-10-05	Hoffmann La Roche	Derivados de malonamida como inhibidores gamma-secretasa.
GB0312365D0 (en)	2003-05-30	2003-07-02	Univ Aston	Novel 3-substituted-1, 4-benzodiazepines
BRPI0413533A (pt)	2003-09-09	2006-10-10	Hoffmann La Roche	derivados de malonamida que bloqueiam a atividade de gama-secretase
EP1795198A1 (en)	2005-12-09	2007-06-13	Hubrecht Laboratorium	Treatment of Barret's esophagus
CA2644136A1 (en)	2006-02-27	2007-09-07	The Johns Hopkins University	Cancer treatment with gamma-secretase inhibitors
MX2008012136A (es)	2006-03-27	2008-10-03	Hoffmann La Roche	Derivados de malonamida como inhibidores de gama secretasa.
WO2008034735A2 (en)	2006-09-20	2008-03-27	F. Hoffmann-La Roche Ag	4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
AU2008287124B2 (en)	2007-08-14	2013-06-06	Eli Lilly And Company	Azepine derivatives as gamma-secretase inhibitors
BRPI0906831A2 (pt)	2008-01-11	2019-09-24	Hoffmann La Roche	uso de um inibidor de gama-secretase para tratamento de câncer
WO2011060051A1 (en)	2009-11-12	2011-05-19	University Of Massachusetts	Methods for treating glioblastoma
US20120225860A1 (en)	2011-03-02	2012-09-06	John Frederick Boylan	Method for administration of a gamma secretase inhibitor

2012
- 2012-02-24 TW TW101106426A patent/TWI530489B/zh active
- 2012-03-21 UY UY0001033961A patent/UY33961A/es active IP Right Grant
- 2012-03-21 AR ARP120100932A patent/AR085471A1/es not_active Application Discontinuation
- 2012-03-22 EA EA201391324A patent/EA022530B1/ru not_active IP Right Cessation
- 2012-03-22 PE PE2013002083A patent/PE20140626A1/es active IP Right Grant
- 2012-03-22 EP EP12711102.9A patent/EP2688873B1/en active Active
- 2012-03-22 BR BR112013024059-8A patent/BR112013024059B1/pt active IP Right Grant
- 2012-03-22 WO PCT/US2012/030021 patent/WO2012129353A1/en not_active Ceased
- 2012-03-22 HR HRP20150273TT patent/HRP20150273T1/hr unknown
- 2012-03-22 PL PL12711102T patent/PL2688873T3/pl unknown
- 2012-03-22 MY MYPI2013003410A patent/MY161233A/en unknown
- 2012-03-22 PH PH1/2013/501738A patent/PH12013501738B1/en unknown
- 2012-03-22 ES ES12711102.9T patent/ES2534080T3/es active Active
- 2012-03-22 RS RS20150150A patent/RS53843B1/sr unknown
- 2012-03-22 PT PT127111029T patent/PT2688873E/pt unknown
- 2012-03-22 KR KR1020137027347A patent/KR101948347B1/ko active Active
- 2012-03-22 AU AU2012230904A patent/AU2012230904B2/en active Active
- 2012-03-22 CN CN201280025022.2A patent/CN103717576B/zh active Active
- 2012-03-22 DK DK12711102T patent/DK2688873T3/en active
- 2012-03-22 MX MX2013010420A patent/MX2013010420A/es active IP Right Grant
- 2012-03-22 US US13/426,730 patent/US8629136B2/en active Active
- 2012-03-22 JP JP2014501220A patent/JP5873923B2/ja active Active
- 2012-03-22 CA CA2830902A patent/CA2830902C/en active Active
- 2012-03-22 SI SI201230162T patent/SI2688873T1/sl unknown
- 2012-03-22 SG SG2013070743A patent/SG193555A1/en unknown
- 2012-03-22 MA MA36323A patent/MA35036B1/fr unknown
2013
- 2013-09-17 CL CL2013002690A patent/CL2013002690A1/es unknown
- 2013-09-17 IL IL228534A patent/IL228534A/en active IP Right Grant
- 2013-09-19 TN TNP2013000372A patent/TN2013000372A1/fr unknown
- 2013-09-20 CO CO13224494A patent/CO6771446A2/es unknown
- 2013-12-09 US US14/100,896 patent/US8822454B2/en active Active
2015
- 2015-04-13 SM SM201500091T patent/SMT201500091B/it unknown
- 2015-04-17 CY CY20151100355T patent/CY1116423T1/el unknown
2023
- 2023-07-07 AR ARP230101776A patent/AR129859A2/es unknown

Also Published As

Publication number	Publication date
PE20140626A1 (es)	2014-05-30
MY161233A (en)	2017-04-14
MX2013010420A (es)	2013-10-01
AU2012230904B2 (en)	2016-03-31
US8822454B2 (en)	2014-09-02
CL2013002690A1 (es)	2014-02-14
WO2012129353A1 (en)	2012-09-27
US20140100365A1 (en)	2014-04-10
TWI530489B (zh)	2016-04-21
EA022530B1 (ru)	2016-01-29
BR112013024059B1 (pt)	2022-01-25
CA2830902C (en)	2019-10-29
US20120245151A1 (en)	2012-09-27
PL2688873T3 (pl)	2015-06-30
EA201391324A1 (ru)	2014-03-31
KR101948347B1 (ko)	2019-02-14
CN103717576A (zh)	2014-04-09
AR129859A2 (es)	2024-10-02
HK1189218A1 (en)	2014-05-30
JP5873923B2 (ja)	2016-03-01
TN2013000372A1 (en)	2015-01-20
ES2534080T3 (es)	2015-04-17
NZ616876A (en)	2014-08-29
AR085471A1 (es)	2013-10-02
PH12013501738B1 (en)	2019-03-13
US8629136B2 (en)	2014-01-14
CO6771446A2 (es)	2013-10-15
IL228534A (en)	2017-02-28
TW201309656A (zh)	2013-03-01
EP2688873B1 (en)	2015-01-21
HRP20150273T1 (hr)	2015-06-19
CY1116423T1 (el)	2017-02-08
EP2688873A1 (en)	2014-01-29
SI2688873T1 (sl)	2015-04-30
SG193555A1 (en)	2013-11-29
KR20140027956A (ko)	2014-03-07
CA2830902A1 (en)	2012-09-27
PT2688873E (pt)	2015-04-14
JP2014511840A (ja)	2014-05-19
UY33961A (es)	2012-09-28
MA35036B1 (fr)	2014-04-03
AU2012230904A1 (en)	2013-11-07
BR112013024059A2 (pt)	2016-12-06
CN103717576B (zh)	2015-11-25
DK2688873T3 (en)	2015-04-27
IL228534A0 (en)	2013-12-31
RS53843B1 (sr)	2015-08-31
PH12013501738A1 (en)	2013-10-07

Publication	Publication Date	Title
SMT201500091B (it)	2015-05-05	Composti di bis(fluoroachil)-1,4-benzodiazepinone
SMT201600308B (it)	2016-11-10	Composti di benzene arile-o eteroarile-sostituiti
LT2751083T (lt)	2018-03-26	Kvinolono junginys
SG11201501573UA (en)	2015-05-28	Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
CO6900145A2 (es)	2014-03-20	Compuesto de ciclopropanoamina
EP2738170A4 (en)	2014-12-31	HETEROCYCLIC CONNECTION
CO6791562A2 (es)	2013-11-14	Compuestos antivirales
BR112014007781A2 (pt)	2017-04-11	compostos anti-virais
BR112014012016A2 (pt)	2017-05-16	compostos
HRP20171005T1 (hr)	2017-09-22	Spojevi imidazopirolidinona
DE112012003620T8 (de)	2014-07-24	Kartusche
HRP20170226T1 (hr)	2017-04-07	Spoj pirazinkarboksamida
CO6910197A2 (es)	2014-03-31	Compuestos novedosos
EP2695881A4 (en)	2014-09-10	guanidine
EP2725017A4 (en)	2014-12-10	CHROME LINK
IL239447A0 (en)	2015-07-30	Novel compounds
DK2804611T3 (da)	2020-11-09	Chitosanafledte forbindelser
EP2748843A4 (en)	2015-03-04	susceptor
BR112013028029A2 (pt)	2017-08-08	composto
BR112014007599A2 (pt)	2017-04-11	compostos anti-virais
IL231235A0 (en)	2014-04-30	Benzothiazolone compound
BR112013033306A2 (pt)	2016-08-16	compostos orgânicos
FR2978994B1 (fr)	2014-10-10	.
FIU20114055U0 (fi)	2011-06-06	Välipohja
BR112014015607A2 (pt)	2017-06-13	composto